NCT02610543 - UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

September 7, 2017

Study Completion Date

December 5, 2017

Conditions

Primary Sjögren's Syndrome

Interventions

DRUG

UCB5857

Active Substance: UCB5857 Pharmaceutical form: Capsule Concentration: 5 mg, 10 mg, 30 mg Route of administration: oral

DRUG

Placebo

Active substance: Placebo Pharmaceutical Form: Capsule Route of administration: oral

Trial Locations (14)

Ss0004 34, Brest

Ss0004 30, Le Kremlin-Bicêtre

Ss0004 35, Strasbourg

Ss0004 20, L’Aquila

Ss0004 21, Palermo

Ss0004 22, Udine

Ss0004 42, Córdoba

Ss0004 40, Villajoyosa

Ss0004 50, Stockholm

Ss0004 01, Birmingham

Ss0004 05, Essex

Ss0004 04, Leeds

Ss0004 03, Newcastle upon Tyne

Ss0004 02, Swindon